RAMUCIRUMAB THERAPY IN PATIENTS WITH ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: A SYSTEMATIC REVIEW
- Authors: Gorbounova V.A1, Besova N.S1, Bychkov M.B1, Orlov S.V2, Kogoniya L.M3, Vozny E.K4, Vladimirova L.U5, Sakaeva D.D6, Sholokhova E.A.7, Minasyan A.A7, Gurochkin A.B7, Cheng R.8, Orlando M.8
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- I.P. Pavlov First St. Petersburg State Medical University
- M.F. Vladimirsky Moscow Regional Research Clinical Institute
- Municipal Clinical Hospital No 57
- Rostov Research Institute of Oncology
- Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Bashkortostan
- Lilly Pharma Ltd
- Eli Lilly & Company
- Issue: Vol 22, No 3 (2017)
- Pages: 116-121
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40403
- DOI: https://doi.org/10.18821/1028-9984-2017-22-3-116-121
- ID: 40403
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
V. A Gorbounova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
N. S Besova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
M. B Bychkov
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
S. V Orlov
I.P. Pavlov First St. Petersburg State Medical UniversitySt. Petersburg, 197022, Russian Federation
L. M Kogoniya
M.F. Vladimirsky Moscow Regional Research Clinical InstituteMoscow, 129110, Russian Federation
E. K Vozny
Municipal Clinical Hospital No 57Moscow, 105077, Russian Federation
L. U Vladimirova
Rostov Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
D. D Sakaeva
Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of BashkortostanUfa, 450054, Russian Federation
Evgeniya A. Sholokhova
Lilly Pharma Ltd
Email: sholokhova_evgeniya@lilly.com
MD, Senior Medical Adviser on Oncology Moscow, 123112, Russian Federation
A. A Minasyan
Lilly Pharma LtdMoscow, 123112, Russian Federation
A. B Gurochkin
Lilly Pharma LtdMoscow, 123112, Russian Federation
R. Cheng
Eli Lilly & CompanyTaipei City, 100, Taiwan
M. Orlando
Eli Lilly & CompanyBuenos Aires, 1430, Argentina
References
- Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 20/09/2016.
- Davydov M.I., Aksel’ E.M. Cancer Statistics in Russia and CIS in 2012. Moscow: Russian Cancer Research Center Publishing Group; 2014. (in Russian)/Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. М.: Издательская группа РОНЦ; 2014.
- Kaprin A.D., Starinskiy V.V., Petrova G.V. (Eds.). Cancer in Russia in 2014 (the Incidence and the Mortality). Moscow: P.A. Gertsen Moscow Research Oncology Institute; 2016. (in Russian)/Каприн А.Д., Стаинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2016.
- Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 2006; 24 (18): 2903-9.
- Kang J.H., Lee S.I., Lim D.H., Park K.W., Oh S.Y., Kwon H.C. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 2012; 30 (13): 1513-8.
- Thuss-Patience P.C., Kretzschmar A., Bichev D., Deist T., Hinke A., Breithaupt K. et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer. 2011; 47 (15): 2306-14.
- Kim S.E., Shim K.N., Jung S.A., Yoo K., Lee J.H. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver. 2009; 3 (2): 88-94.
- Tian S., Quan H., Xie C., Guo H., Lü F., Xu Y. et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011; 102 (7): 1374-80.
- Spratlin J.L., Cohen R.B., Eadens M., Gore L., Camidge D.R., Diab S. et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010; 28 (5): 780-7.
- Doebele R.C., Spigel D., Tehfe M., Thomas S., Reck M., Verma S. et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015; 121 (6): 883-92.
- Garon E.B., Ciuleanu T.E., Arrieta O., Prabhash K., Syrigos K.N., Goksel T. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384 (9944): 665-73.
- Fuchs C.S., Tomasek J., Yong C.J., Dumitru F., Passalacqua R., Goswami C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383 (9911): 31-9.
- Wilke H., Muro K., Van Cutsem E., Oh S.C., Bodoky G., Shimada Y. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15 (11): 1224-35.
- Tabernero J., Yoshino T., Cohn A.L., Obermannova R., Bodoky G., Garcia-Carbonero R. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015; 16 (5): 499-508.
- Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 2009; 62 (10): 1006-12.
- Fuchs C.S., Tabernero J., Tomasek J., Chau I., Melichar B., Safran H. et al. Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL). J. Clin. Oncol. 2015; 33 (Suppl.): Abstr. 4029.
- Muro K., Bodoky G., Cesas A., Chao Y., Clingan P., Hironaka S. et al. RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy - An age-group analysis. J. Clin. Oncol. 2015; 33 (Suppl. 3): Abstr. 11.
- Muro K., Oh S.C., Shimada Y., Lee K.W., Yen C.J., Chao Y. et al. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. J. Gastroenterol. Hepatol. 2016; 31 (3): 581-9.
- Shitara K., Muro K., Shimada Y., Hironaka S., Sugimoto N., Komatsu Y. et al. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2016; 19 (3): 927-38.
- Al-Batran S.E., Van Cutsem E., Oh S.C., Bodoky G., Shimada Y., Hironaka S. et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann. Oncol. 2016; 27 (4): 673-9.
- Yoon H.H., Bendell J.C., Braiteh F.S., Firdaus I., Philip P.A., Cohn A.L. et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: randomized, double-blind, multicenter phase II trial. Ann. Oncol. 2016; 27(12): 2196-203.
- Tabernero J., Ohtsu A., Muro K., Van Cutsem E., Oh S.C., Bodoky G. et al. Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J. Clin. Oncol. 2015; 33 (Suppl. 3): Abstr. 121.
- Fuchs C.S., Tabernero J., Al-Batran S.E., Chau I., Ilson D.H., Van Cutsem E. et al. A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). J. Clin. Oncol. 2015; 33 (Suppl.): Abstr. TPS4131.
- Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int. J. Cancer. 2002; 97 (3): 393-9.
- Hsu C., Shen Y.C., Cheng C.C., Cheng A.L., Hu F.C., Yeh K.H. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer. 2012; 15 (3): 265-80.
- Kim J., Sun C.L., Mailey B., Prendergast C., Artinyan A., Bhatia S. et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann. Oncol. 2010; 21 (1): 152-60.
- Gill S., Shah A., Le N., Cook E.F., Yoshida E.M. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J. Clin. Oncol. 2003; 21 (11): 2070-6.
- Li J., Qin S., Xu J., Xiong J., Wu C., Bai Y. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 2016; 34 (13): 1448-54.
- Cristescu R., Lee J., Nebozhyn M., Kim K.M., Ting J.C., Wong S.S. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Med. 2015; 21 (5): 449-56.